Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas

Summary

To assess the efficacy and safety of Temozolomide for second-line treatment of Neuroendocrine Carcinomas progressing after first-line Platinum-based therapy.

Timeline

Start

2017-01-29

Primary completion

2017-12-30

Completion

2019-12-16

Publications

• von Arx C, Della Vittoria Scarpati G, Cannella L, Clemente O, Marretta AL, Bracigliano A, Picozzi F, Iervolino D, Granata V, Modica R, Bianco A, Mocerino C, Di Mauro A, Pizzolorusso A, Di Sarno A, Ottaiano A, Tafuto S; ENETs Center of Excellence in Naples, Italy and with the endorsement of the Italian Association for Neuroendocrine Tumor IT.A.NET. A new schedule of one week on/one week off temozolomide as second-line treatment of advanced neuroendocrine carcinomas (TENEC-TRIAL): a multicenter, open-label, single-arm, phase II trial. ESMO Open. 2024 May;9(5):103003. doi: 10.1016/j.esmoop.2024.103003. Epub 2024 Apr 13.

Drugs

Indications